

Retractable Technologies, Inc.
510(k) Submission Date: 10/12/11

PREMARKET NOTIFICATION
510(k) SUMMARY OF SAFETY AND EFFECTIVENESS FOR
VANISHPOINT® BLOOD COLLECTION SET
(21 CFR 807.92)

Applicant Name:	Retractable Technologies, Inc. 511 Lobo Lane Little Elm, TX 75068
Phone:	972-294-1010
Contact Person:	Rhonda Wells Regulatory Affairs Manager
Date of Summary Preparation:	October 12, 2011
Trade Name:	VanishPoint® Blood Collection Set
Common Name:	Blood Collection Set
Classification Name:	Tubes, Vials, Systems, Serum Separators, Blood
Collection	
Device Classification:	Class II
Legally Marketed Substantially Equivalent Device:	
	K030573 – BD Vacutainer Push Button Blood Collection Set
Description of Device:	The VanishPoint® Blood Collection Set is designed to collect blood specimens from patients. The VanishPoint® Blood Collection Set aids in the prevention of needlestick injuries through its retraction mechanism. The device will initially be available with either 7" or 12" tubing, $\frac{3}{4}$ " length needles and gauge sizes of 19, 21, 23 and 25.
Intended Use:	The intended use of the VanishPoint® Blood Collection Set is to provide safe and reliable access to the vascular system to obtain blood specimens from patients. It may be used for any patient population with consideration given to adequacy of vascular anatomy and appropriateness of procedure.
	The VanishPoint® Blood Collection Set aids in the prevention of needlestick injuries.
	The predicate device is indicated for both blood collection and intravenous administration of fluids
Engineering Testing:	Various applicable performance tests were performed on the VanishPoint® Blood Collection Set. Some of the tests are needle pullout force, trigger force, tubing connection strength, tubing strength, air, liquid leakage and complete needle retraction. The subject device performed as expected in all areas of testing.

Retractable Technologies, Inc.
510(k) Submission Date: 10/12/11

Simulated Use Study:

A simulated use study utilizing healthcare professionals was performed using the VanishPoint® Blood Collection set in a variety of uses. The subject device was found suitable for the intended use.

Comparison of Technical Characteristics:

The subject VanishPoint® Blood Collection Set and the predicate device are similar in design, technological characteristics and materials. Biocompatibility testing was performed on all materials in the subject device with acceptable results. Both devices labeled to obtain blood specimens from patients.

Substantial Equivalence:

The operation, similar design and materials between the predicate devices and the subject device do not raise new issues of safety and effectiveness. The difference in indications does not affect the safety and effectiveness of the subject device when used as labeled. It is our opinion that the devices are substantially equivalent.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room -WO66-G609
Silver Spring, MD 20993-0002

Ms. Rhonda Wells
Regulatory Affairs Manager
Retractable Technologies, Incorporated
511 Lobo Lane
Little Elm, Texas 75068

OCT 20 2011

Re: K112512

Trade/Device Name: VanishPoint® Blood Collection Set
Regulation Number: 21 CFR 880.5440
Regulation Name: Intravascular Administration Set
Regulatory Class: II
Product Code: FPA, JKA
Dated: August 23, 2011
Received: August 31, 2011

Dear Ms. Wells:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOFFICES/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,



Anthony D. Watson, B.S., M.S., M.B.A.
Director
Division of Anesthesiology, General Hospital,
Infection Control and Dental Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

INDICATIONS FOR USE STATEMENT

510(k) Number (if known): K112512

Device Name: VanishPoint® Blood Collection Set

Indications for Use:

The intended use of the VanishPoint® Blood Collection Set is to provide safe and reliable access to the vascular system to obtain blood specimens from patients. It may be used for any patient population with consideration given to adequacy of vascular anatomy and appropriateness of procedure.

The VanishPoint Blood Collection Set aids in the prevention of needlestick injuries.

Prescription Use ✓ AND/OR Over-The-Counter Use _____
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

RH C. A. 10/19/11

(Optional Format 3-10-98)

(Division Sign-Off)

Division of Anesthesiology, General Hospital
Infection Control, Dental Devices

510(k) Number: K112512